Prostate Cancer Expert Panel Positive on Medivation's (MDVN) Xtandi, UBS Says; Shares Worth Up to $75 in Takeout
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
Go back to Prostate Cancer Expert Panel Positive on Medivation's (MDVN) Xtandi, UBS Says; Shares Worth Up to $75 in Takeout
March 31, 2016 11:40 AM EDT
Looking through the rumors, Jefferies analyst, Biren Amin, values shares of Medivation (NASDAQ: MDVN) in baseline and synergistic scenarios. However, he made no change to his Hold rating or $39 PT.
The baseline scenario values MDVN at $39/share thru a DCF, and included $200M of annual synergies from OpEx. The analyst assumed the acquirers tax rate and calculated a potential... More
March 31, 2016 10:12 AM EDT
Medivation (NASDAQ: MDVN), up early on takeover speculation, just crossed above its 200 Day Moving Average.
Shares are up 17.4% early to $43.89
...
More
March 31, 2016 9:31 AM EDT
Eagle Bulk Shipping, Inc. (Nasdaq: EGLE) 40% LOWER; announced that it has reached an agreement with the Company's lenders and holders of approximately 75% of the Company's outstanding equity for a comprehensive balance-sheet recapitalization. The transaction provides Eagle Bulk with approximately $105 million in incremental liquidity,... More
March 31, 2016 6:24 AM EDT
Credit Suisse analyst Kennen MacKay bumped his price target on Medivation (NASDAQ: MDVN) to $49.00 (from $48.00) following reports the company hired bankers to fend off a takeover. The firm maintained an Outperform rating.
The analyst notes Medivation has become vulnerable to a takeover given the... More
